학술논문
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
Document Type
Journal
Author
Tannir, Nizar M.; McDermott, David F.; Escudier, Bernard; Hammers, Hans J.; Aren, Osvaldo Rudy; Plimack, Elizabeth R.; Barthelemy, Philippe; Neiman, Victoria; George, Saby; Porta, Camillo; Powles, Thomas; Donskov, Frede; Grimm, Marc-Oliver; Amin, Asim; Tykodi, Scott S.; Tomita, Yoshihiko; Rini, Brian I.; McHenry, M. Brent; Saggi, Shruti Shally; Motzer, Robert J.
Source
Subject
Language
English
ISSN
15277755